Edition:
India

Alterity Therapeutics Ltd (ATHE.OQ)

ATHE.OQ on NASDAQ Stock Exchange Capital Market

0.91USD
6 Dec 2019
Change (% chg)

$0.00 (-0.00%)
Prev Close
$0.91
Open
$0.85
Day's High
$0.91
Day's Low
$0.85
Volume
7,151
Avg. Vol
1,958
52-wk High
$2.72
52-wk Low
$0.85

Summary

Name Age Since Current Position

Geoffrey Kempler

2005 Executive Chairman of the Board, Chief Executive Officer

Kathryn Andrews

2014 Chief Financial Officer

David Stamler

2017 Chief Medical Officer and Senior Vice President Clinical Development

Phillip Hains

2014 Company Secretary

Tristan Edwards

2019 Director

David Sinclair

2019 Director

Lawrence Gozlan

2011 Non-Executive Independent Director

Peter Marks

2005 Non-Executive Independent Director

Brian Meltzer

1999 Non-Executive Independent Director

Rebecca Wilson

2019 IR Contact Officer

Biographies

Name Description

Geoffrey Kempler

Mr. Geoffrey Paul Kempler serves as an Executive Chairman of the Board and Chief Executive Officer of Prana Biotechnology Ltd. Mr Kempler has served as Chairman of our Board of Directors since November 1997, between November 1997 and August 2004 he served as our Chief Executive Officer, and in June 2005 he again assumed the position of Chief Executive Officer. Mr Kempler is one of the founders of the Group. Mr Kempler is a qualified psychologist. Mr Kempler, who has extensive experience in investment and business development, has been responsible for the implementation of our strategic plan and the commercialisation of our technology.

Kathryn Andrews

Ms. Kathryn Andrews serves as a Chief Financial Officer of Prana Biotechnology Ltd. She is a Certified Practicing Accountant and has over 25 years’ experience in accounting, commercial management and consulting in various roles. For the past two years Ms. Andrews has held a senior role with The CFO Solution, a firm focused on the listed company and life sciences environments.

David Stamler

Phillip Hains

Mr. Phillip Hains serves as a Company Secretary of Prana Biotechnology Ltd. He is a Chartered Accountant operating a specialist public practice, 'The CFO Solution'. The CFO Solution focuses on providing back office support, financial reporting and compliance systems for listed public companies. A specialist in the public company environment, Mr. Hains has served the needs of a number of company boards and their related committees. He has over 20 years' experience in providing businesses with accounting, administration, compliance and general management services. He holds a Master of Business Administration from RMIT and a Public Practice Certificate from the Institute of Chartered Accountants.

Tristan Edwards

David Sinclair

Lawrence Gozlan

Mr. Lawrence Gozlan serves as a Non-Executive Independent Director of Prana Biotechnology Ltd. Mr. Gozlan, a leading biotechnology investor and advisor, is the Chief Investment Officer and Founder of Scientia Capital, a specialised global investment fund focused exclusively in life sciences. Scientia Capital was founded to provide high level expertise and to manage investments for high net worth individuals, family offices and institutional investors wanting exposure to the biotechnology industry. Prior to this, Mr. Gozlan was responsible for the largest biotechnology investment portfolio in Australia as the institutional biotechnology analyst at QIC (“the Queensland Investment Corporation”), an investment fund with over A$60 billion under management. He previously worked as the senior biotechnology analyst in the equities team at Foster Stockbroking Pty Ltd, and gained senior corporate finance experience advising life sciences companies at Deloitte. Mr. Gozlan is currently a Director of AusBiotech, which is the Australian Biotechnology Industry body and a number of private biotechnology companies in the USA. He holds a Bachelor of Science with Honors in microbiology and immunology from the University of Melbourne specializing in neurodegenerative diseases.

Peter Marks

Mr. Peter Ashley Marks serves as a Non-Executive Independent Director of Prana Biotechnology Ltd. the period November 21, 2006 to October 20, 2011, Mr. Marks has also served as Executive Chairman of iSonea Ltd, formerly KarmelSonix Ltd, a medical devices company listed on the ASX that was focused on developing and commercializing a range of devices in the respiratory and medicine space. For over 13 years until the end of August 2014, Mr. Marks was a Director of Peregrine Corporate Ltd, an Australianbased investment bank. Mr. Marks was until late 2016, a Director of Armadale Capital Plc (formerly Watermark Global Plc), an AIM listed investment company, focused on natural resources projects based principally in Africa with its current major investments being a gold exploration company in DRC and a coal briquetting operation in South Africa. Mr. Marks is currently a Principal of Henslow Pty Ltd (formerly Halcyon Corporate Pty Ltd), a corporate and capital markets advisory firm specializing in advising small to mid-cap companies. Mr. Marks is a non-executive Director of Fluence Corporation Ltd. (formerly Emefcy Group Limited and prior to that Savcor Group Limited), an ASX listed industrial waste water technology business. Mr. Marks is also a non-executive director of Terragenic International Ltd, an unlisted public company developing a novel hydrogen fuel system for vehicles. He also currently serves as Chairman of ASX listed biotech company, Noxopharm Ltd. which is progressing a clinical program in using chemical sensitisers to enhance the effectiveness of existing chemotherapy drugs and radiation therapies. From September 1998 until March 2001, Mr. Marks was employed by KPMG Corporate Finance Ltd (Australia), where he rose to Director and was responsible for heading up the equity capital markets group in Melbourne.

Brian Meltzer

Mr. Brian Derek Meltzer serves as a Non-Executive Independent Director of Prana Biotechnology Ltd., since December 9, 1999. Mr. Meltzer has over 30 years’ experience in economics, finance and investment banking. Until mid-2014, Mr. Meltzer was a Director of a venture capital entity, licensed by the government as an Innovation Investment Fund with investments including biotechnology. Mr Meltzer is a Non-Executive Director on the boards of a number of private companies. He is also a Director on the board of the Australian-Israel Chamber of Commerce and is Chairman of Independence Australia (previously Paraquad).

Rebecca Wilson

Basic Compensation

Name Fiscal Year Total

Geoffrey Kempler

644,152

Kathryn Andrews

231,124

David Stamler

630,151

Phillip Hains

100,000

Tristan Edwards

--

David Sinclair

--

Lawrence Gozlan

118,750

Peter Marks

118,750

Brian Meltzer

141,250

Rebecca Wilson

--
As Of  30 Jun 2018